Overexpression of Asparaginyl Endopeptidase is Significant for Esophageal Carcinoma Metastasis and Predicts Poor Patient Prognosis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 6

PMID 29399177

Citations 6

Authors

Xinyang Liu

Zhichao Wang

Guoliang Zhang

Qikun Zhu

Hui Zeng

Tao Wang

Feng Gao

Zhan Qi

Jinwen Zhang

Rui Wang

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer is one of the most common types of cancer with poor prognosis. The molecular mechanisms of esophageal cancer progression remain unknown. In the present study, the aim was to investigate the clinical significance and biological function of protease asparaginyl endopeptidase (AEP) in esophageal cancer. The expression of AEP in esophageal cancer was examined, and its association with clinicopathological factors and patient prognosis was analyzed. A series of functional and mechanistic assays were performed to further investigate the underlying molecular mechanisms, and functions in esophageal cancer. The expression of AEP was elevated in esophageal cancer tissues, and patients with high AEP expression displayed a significantly shorter survival time compared with those with low AEP expression. In addition, loss of function experiments demonstrated that knockdown of AEP significantly reduced the migration and invasion ability of esophageal cancer cells. Furthermore, the pro-oncogenic effects of AEP in esophageal cancer were mediated by the upregulation of matrix-metalloproteinase 2 and 3. Taken together, the data from the present study indicates that high AEP expression is associated with esophageal cancer progression and AEP is an indicator of poor prognosis in patients with esophageal cancer. AEP therefore, may be considered as a novel prognostic biomarker or potential therapeutic target in esophageal cancer.

Citing Articles

Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy.

Conesa-Bakkali R, Morillo-Huesca M, Martinez-Fabregas J Cells. 2025; 14(2).

PMID: 39851495 PMC: 11763575. DOI: 10.3390/cells14020068.

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.

Xu X, Liu M, Peng K, Yu Y, Liu T Clin Transl Oncol. 2023; 25(3):776-785.

PMID: 36609651 PMC: 9941237. DOI: 10.1007/s12094-022-02986-6.

The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.

Zhang W, Lin Y Cells. 2021; 10(5).

PMID: 34068767 PMC: 8151911. DOI: 10.3390/cells10051153.

Extracellular Vesicles (EVs) and Pancreatic Cancer: From the Role of EVs to the Interference with EV-Mediated Reciprocal Communication.

Moeng S, Son S, Lee J, Lee H, Kim T, Choi S Biomedicines. 2020; 8(8).

PMID: 32756339 PMC: 7459718. DOI: 10.3390/biomedicines8080267.

Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway.

Wang T, Wang J, Ren W, Liu Z, Cheng Y, Zhang X Thorac Cancer. 2020; 11(8):2316-2324.

PMID: 32657048 PMC: 7396387. DOI: 10.1111/1759-7714.13570.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Murray G, Duncan M, ONeil P, McKay J, Melvin W, Fothergill J . Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998; 185(3):256-61. DOI: 10.1002/(SICI)1096-9896(199807)185:3<256::AID-PATH115>3.0.CO;2-A. View

Vermeulen E, Zamora-Ros R, Duell E, Lujan-Barroso L, Boeing H, Aleksandrova K . Dietary flavonoid intake and esophageal cancer risk in the European prospective investigation into cancer and nutrition cohort. Am J Epidemiol. 2013; 178(4):570-81. DOI: 10.1093/aje/kwt026. View

Dickinson D . Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit Rev Oral Biol Med. 2002; 13(3):238-75. DOI: 10.1177/154411130201300304. View

Choi S, Reddy S, Devlin R, Menaa C, Chung H, Boyce B . Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem. 1999; 274(39):27747-53. DOI: 10.1074/jbc.274.39.27747. View

Gawenda J, Traub F, Luck H, Kreipe H, von Wasielewski R . Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 2006; 102(1):1-6. DOI: 10.1007/s10549-006-9311-z. View

Pennathur A, Farkas A, Krasinskas A, Ferson P, Gooding W, Gibson M . Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009; 87(4):1048-54. PMC: 2912110. DOI: 10.1016/j.athoracsur.2008.12.060. View

Liu C, Sun C, Huang H, Janda K, Edgington T . Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003; 63(11):2957-64. View

Harris K, Durek T, Kaas Q, Poth A, Gilding E, Conlan B . Efficient backbone cyclization of linear peptides by a recombinant asparaginyl endopeptidase. Nat Commun. 2015; 6:10199. PMC: 4703859. DOI: 10.1038/ncomms10199. View

10.

Xing W, Baylink D, Kesavan C, Hu Y, Kapoor S, Chadwick R . Global gene expression analysis in the bones reveals involvement of several novel genes and pathways in mediating an anabolic response of mechanical loading in mice. J Cell Biochem. 2005; 96(5):1049-60. DOI: 10.1002/jcb.20606. View

11.

Enzinger P, Mayer R . Esophageal cancer. N Engl J Med. 2003; 349(23):2241-52. DOI: 10.1056/NEJMra035010. View

12.

Liu X, Wang Z, Zhang G, Zhu Q, Zeng H, Wang T . High TRAF6 Expression Is Associated With Esophageal Carcinoma Recurrence and Prompts Cancer Cell Invasion. Oncol Res. 2016; 25(4):485-493. PMC: 7841001. DOI: 10.3727/096504016X14749340314441. View

13.

Descamps D, Le Gars M, Balloy V, Barbier D, Maschalidi S, Tohme M . Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing. Proc Natl Acad Sci U S A. 2012; 109(5):1619-24. PMC: 3277124. DOI: 10.1073/pnas.1108464109. View

14.

Sepulveda F, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E . Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity. 2009; 31(5):737-48. DOI: 10.1016/j.immuni.2009.09.013. View

15.

Miller G, Matthews S, Reinheckel T, Fleming S, Watts C . Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 2011; 25(5):1606-17. DOI: 10.1096/fj.10-172312. View

16.

Zheng J, Xu C, Chu D, Zhang X, Li J, Ji G . Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis. Immunol Lett. 2014; 161(1):13-9. DOI: 10.1016/j.imlet.2014.04.007. View

17.

Chen J, Dando P, Rawlings N, Brown M, Young N, Stevens R . Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem. 1997; 272(12):8090-8. DOI: 10.1074/jbc.272.12.8090. View

18.

Holland M, Castro F, Alexander S, Smith D, Liu J, Walker M . RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood. 2011; 118(3):638-49. DOI: 10.1182/blood-2010-09-307330. View

19.

Murthy R, Arbman G, Gao J, Roodman G, Sun X . Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005; 11(6):2293-9. DOI: 10.1158/1078-0432.CCR-04-1642. View

20.

Zhao L, Hua T, Crowley C, Ru H, Ni X, Shaw N . Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage. Cell Res. 2014; 24(3):344-58. PMC: 3945893. DOI: 10.1038/cr.2014.4. View